Register Now for the IMF Patient and Family Seminar 2024 in Boca Raton, FL

The International Myeloma Foundation (IMF) is excited to announce that the 2024 Boca Raton Patient and Family Seminar will take place on March 15-16, 2024, in Boca Raton, Florida. The seminar is FREE, but in-person seating is LIMITED.

Some of the presenters include IMF President and CEO Yelak Biru, Dr. Saad Usmani (Memorial Sloan Kettering — New York), Dr. Matthew Drake (Mayo Clinic — Rochester, MN), Dr. Gurbakhash Kaur (UT Southwestern Medical Center — Dallas), Dr. Peter Voorhees (Atrium Health, Levine Cancer Center — Charlotte, NC), and IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope Cancer Center – Scottsdale, AZ). Also presenting at the meeting will be IMF InfoLine Advisor Teresa Miceli, RN, BSN, OCN; IMF Vice President of Patient Support Robin Tuohy; Patient Advocate/Support Group Leader Michael Tuohy; Wendy Thomas, RN (University of Kansas Cancer Center — Kansas City, KS); and Amanda Goodstadt, Esq., Senior Staff Attorney at Triage Cancer.

Watch the Replay: Top Myeloma Research at ASH 2023 from a Patient Perspective

IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie discussed important Top Myeloma Research and Key Takeaways from the 2023 American Society of Hematology (ASH) Conference, along with a panel of patient advocates including Jessie Daw, PhD, and Michael Tuohy. Together, they sifted through the data of 1,000+ myeloma-related abstracts from the ASH conference and presented key points in approachable terms for everyday decision-making. The replay of this webinar and its slides are now available.

Register Early for the March for Myeloma 5K Run/Walk

This isn't just a run; it's a force for change. During March, we're creating a global wave of awareness for myeloma. This Myeloma ACTION Month, march alongside others in the myeloma community and help us make waves of awareness that touch every corner of the globe. Join us in-person in Boca Raton, FL, or race virtually from wherever you are on Friday, March 15, 2024, at 7:00 a.m EST as we make this journey a pivotal part of Myeloma Action Month 2024.

Watch the IMF’s Videos with Key Opinion Leaders from ASH 2023

In this video, Dr. Niels W.C.J. van de Donk discusses the safety and clinical activity of 3 different doses of iberdomide as a novel maintenance treatment post-transplant in newly diagnosed multiple myeloma patients. Watch it from the button below and see all of the IMF’s coverage of ASH 2023 here.

Around the Web: Myeloma News

To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. According to this article, new research published in Blood Advances shows that “researchers find that weight, smoking habits, and exercise may impact one’s likelihood of developing multiple myeloma.” This article reports on the BOSTON Trial, which evaluated Xprovio® (selinexor) in myeloma patients and “found that adapting the starting dose based on initial adverse effects (AEs) yielded promising results, including improved efficacy, reduced AE rates, and a better quality-of-life.” Finally, Starton Therapeutics reports on “initial key safety and efficacy signals of its STAR-LLD Phase 1b clinical trial in multiple myeloma.” As always, we invite you to visit the IMF Newsroom for the most recent myeloma news.